<DOC>
	<DOC>NCT01747538</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of gevokizumab in reducing the risk of recurrent uveitic disease in subjects with non-infectious uveitis whose disease is currently controlled with systemic treatment.</brief_summary>
	<brief_title>Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Diagnosis of noninfectious intermediate, posterior, or pan uveitis in at least one eye Controlled uveitic disease in both eyes Stable dose of oral corticosteroids in combination with selected stable immunosuppressive therapy Effective contraceptive measures Infectious uveitis and masquerade syndromes Isolated anterior uveitis Contraindication to mydriatics Active tuberculosis disease History of allergic or anaphylactic reactions to monoclonal antibodies History of recurrent infection or predisposition to infection; active ocular infection Pregnant or nursing women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Panuveitis</keyword>
</DOC>